Gold Standard Diagnostics (GSD) has launched a new Lyme Disease serologic assay, the B. burgdorferi IgG/IgM VlsE-OspC ELISA.
This assay has been FDA cleared for use as an integral part of the Modified Two-Tiered Testing algorithm (MTTT) available from GSD.
"Using the B. burgdorferi IgG/IgM VlsE-OspC test in combination with a second GSD Lyme EIA, we maintain >98% specificity while demonstrating a nearly 20% increase in early Lyme disease detection compared with the Standard Two-Tiered Testing algorithm (STTT)", said GSD in a press release.
Gold Standard Diagnostics is the only company offering kits in the U.S. to fulfill Lyme testing requirements for both the Standard and Modified two-tiered testing algorithms. Their four EIA kits and two Immunoblot kits allow flexibility for a lab to meet their clients’ needs.
Image: Modified Two-Tiered Testing Algorithm (Credit: GSD)
If you want further details about this product, please use the 'Request Information' button below.
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.
